Patents by Inventor Markus CONZELMANN
Markus CONZELMANN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240150386Abstract: The present invention is directed to a method for modifying the retention time of RNA on a chromatographic column. The present invention also concerns a method for purifying RNA from a mixture of at least two RNA species. Furthermore, the present invention relates to a method for co-purifying at least two RNA species from a mixture of at least two RNA species. In particular, the present invention provides a method for harmonizing the numbers of A and/or U nucleotides in at least two RNA species. The present invention is also directed to RNA obtainable by said methods, a composition comprising said RNA or a vaccine comprising said RNA and methods for producing such RNA and compositions. Further, the invention concerns a kit, particularly a kit of parts, comprising the RNA, composition or vaccine. The invention is further directed to a method of treating or preventing a disorder or a disease, first and second medical uses of the RNA, composition and vaccine.Type: ApplicationFiled: May 19, 2023Publication date: May 9, 2024Applicant: CureVac SEInventors: Stefan HEINZ, Tilmann ROOS, Dominik VAHRENHORST, Markus CONZELMANN
-
Publication number: 20240100142Abstract: The invention relates to a method for producing a ribonucleic acid (RNA) molecule composition comprising n different RNA molecule species, the method comprising a step of RNA in vitro transcription of a mixture of m different deoxyribonucleic acid (DNA) molecule species in a single reaction vessel in parallel, i.e. simultaneously, and a step of obtaining the RNA molecule composition. Also provided is the RNA composition provided by the inventive method and a pharmaceutical composition comprising the same as well as a pharmaceutical container. Moreover, the invention provides the RNA composition and the pharmaceutical composition for use as medicament.Type: ApplicationFiled: May 11, 2023Publication date: March 28, 2024Applicant: CureVac SEInventors: Tilmann ROOS, Martin KUNZE, Benyamin YAZDAN PANAH, Salih YILMAZ, Markus CONZELMANN
-
Publication number: 20230227881Abstract: The present invention relates to an immobilized capping enzyme, preferably an immobilized Vaccinia virus capping enzyme. Furthermore, the present invention relates to an immobilized cap-specific nucleoside 2?-O-methyltransferase, preferably an immobilized Vaccinia virus cap-specific nucleoside 2?-O-methyltransferase. Moreover, the present invention relates to a method for immobilizing said enzymes and to a method of using said enzymes for the addition of a 5?-cap structure to RNAs. Moreover, the present invention relates to an enzyme reactor for performing the capping reaction using said immobilized enzymes and the subsequent separation of the 5?-capped RNA product. In addition, the present invention relates to a kit comprising the capping enzyme and/or the cap-specific nucleoside 2?-O-methyltransferase.Type: ApplicationFiled: January 13, 2023Publication date: July 20, 2023Applicant: CureVac SEInventors: Tilmann ROOS, Benyamin YAZDAN PANAH, Markus CONZELMANN, Andreas THESS, Dominik BUOB, Martin KUNZE, Veronika WAGNER
-
Patent number: 11692002Abstract: The present invention is directed to a method for modifying the retention time of RNA on a chromatographic column. The present invention also concerns a method for purifying RNA from a mixture of at least two RNA species. Furthermore, the present invention relates to a method for co-purifying at least two RNA species from a mixture of at least two RNA species. In particular, the present invention provides a method for harmonizing the numbers of A and/or U nucleotides in at least two RNA species. The present invention is also directed to RNA obtainable by said methods, a composition comprising said RNA or a vaccine comprising said RNA and methods for producing such RNA and compositions. Further, the invention concerns a kit, particularly a kit of parts, comprising the RNA, composition or vaccine. The invention is further directed to a method of treating or preventing a disorder or a disease, first and second medical uses of the RNA, composition and vaccine.Type: GrantFiled: November 8, 2018Date of Patent: July 4, 2023Assignee: CureVac SEInventors: Stefan Heinz, Tilmann Roos, Dominik Vahrenhorst, Markus Conzelmann
-
Patent number: 11684665Abstract: The invention relates to a method for producing a ribonucleic acid (RNA) molecule composition comprising n different RNA molecule species, the method comprising a step of RNA in vitro transcription of a mixture of m different deoxyribonucleic acid (DNA) molecule species in a single reaction vessel in parallel, i.e. simultaneously, and a step of obtaining the RNA molecule composition. Also provided is the RNA composition provided by the inventive method and a pharmaceutical composition comprising the same as well as a pharmaceutical container. Moreover, the invention provides the RNA composition and the pharmaceutical composition for use as medicament.Type: GrantFiled: December 22, 2016Date of Patent: June 27, 2023Assignee: CureVac SEInventors: Tilmann Roos, Martin Kunze, Benyamin Yazdan Panah, Salih Yilmaz, Markus Conzelmann
-
Patent number: 11608513Abstract: The present invention relates to an immobilized capping enzyme, preferably an immobilized Vaccinia virus capping enzyme. Furthermore, the present invention relates to an immobilized cap-specific nucleoside 2?-O-methyltransferase, preferably an immobilized Vaccinia virus cap-specific nucleoside 2?-O-methyltransferase. Moreover, the present invention relates to a method for immobilizing said enzymes and to a method of using said enzymes for the addition of a 5?-cap structure to RNAs. Moreover, the present invention relates to an enzyme reactor for performing the capping reaction using said immobilized enzymes and the subsequent separation of the 5?-capped RNA product. In addition, the present invention relates to a kit comprising the capping enzyme and/or the cap-specific nucleoside 2?-O-methyltransferase.Type: GrantFiled: May 30, 2016Date of Patent: March 21, 2023Assignee: CureVac SEInventors: Tilmann Roos, Benyamin Yazdan Panah, Markus Conzelmann, Andreas Thess, Dominik Buob, Martin Kunze, Veronika Wagner
-
Publication number: 20220348976Abstract: The present invention relates to an immobilized poly(N)polymerase (PNP), methods of producing said PNP and uses thereof. Further disclosed is an enzyme reactor and kit comprising the PNP for producing polynucleotidylated ribonucleic acid (poly(N)RNA) molecules which are useful in gene therapy, immunotherapy, protein replacement therapy and/or vaccination.Type: ApplicationFiled: June 13, 2022Publication date: November 3, 2022Applicant: CureVac AGInventors: Tilmann ROOS, Benyamin YAZDAN PANAH, Markus CONZELMANN, Veronika WAGNER
-
Patent number: 11384375Abstract: The present invention relates to an immobilized poly(N)polymerase (PNP), methods of producing said PNP and uses thereof. Further disclosed is an enzyme reactor and kit comprising the PNP for producing polynucleotidylated ribonucleic acid poly(N)RNA)molecules which are useful in gene therapy, immunotherapy, protein replacement therapy and/or vaccination.Type: GrantFiled: May 2, 2016Date of Patent: July 12, 2022Assignee: CureVac AGInventors: Tilmann Roos, Benyamin Yazdan Panah, Markus Conzelmann, Veronika Wagner
-
Publication number: 20220144877Abstract: The present invention is directed to a method for modifying the retention time of RNA on a chromatographic column. The present invention also concerns a method for purifying RNA from a mixture of at least two RNA species. Furthermore, the present invention relates to a method for co-purifying at least two RNA species from a mixture of at least two RNA species. In particular, the present invention provides a method for harmonizing the numbers of A and/or U nucleotides in at least two RNA species. The present invention is also directed to RNA obtainable by said methods, a composition comprising said RNA or a vaccine comprising said RNA and methods for producing such RNA and compositions. Further, the invention concerns a kit, particularly a kit of parts, comprising the RNA, composition or vaccine. The invention is further directed to a method of treating or preventing a disorder or a disease, first and second medical uses of the RNA, composition and vaccine.Type: ApplicationFiled: November 8, 2018Publication date: May 12, 2022Applicant: CureVac AGInventors: Stefan HEINZ, Tilmann ROOS, Dominik VAHRENHORST, Markus CONZELMANN
-
Publication number: 20190083602Abstract: The invention relates to a method for producing a ribonucleic acid (RNA) molecule composition comprising n different RNA molecule species, the method comprising a step of RNA in vitro transcription of a mixture of m different deoxyribonucleic acid (DNA) molecule species in a single reaction vessel in parallel, i.e. simultaneously, and a step of obtaining the RNA molecule composition. Also provided is the RNA composition provided by the inventive method and a pharmaceutical composition comprising the same as well as a pharmaceutical container. Moreover, the invention provides the RNA composition and the pharmaceutical composition for use as medicament.Type: ApplicationFiled: December 22, 2016Publication date: March 21, 2019Inventors: Tilmann ROOS, Martin KUNZE, Benyamin YAZDAN PANAH, Salih YILMAZ, Markus CONZELMANN
-
Publication number: 20180237817Abstract: The present invention relates to an immobilized capping enzyme, preferably an immobilized Vaccinia virus capping enzyme. Furthermore, the present invention relates to an immobilized cap-specific nucleoside 2?-O-methyltransferase, preferably an immobilized Vaccinia virus cap-specific nucleoside 2?-O-methyltransferase. Moreover, the present invention relates to a method for immobilizing said enzymes and to a method of using said enzymes for the addition of a 5?-cap structure to RNAs. Moreover, the present invention relates to an enzyme reactor for performing the capping reaction using said immobilized enzymes and the subsequent separation of the 5?-capped RNA product. In addition, the present invention relates to a kit comprising the capping enzyme and/or the cap-specific nucleoside 2?-O-methyltransferase.Type: ApplicationFiled: May 30, 2016Publication date: August 23, 2018Inventors: Tilmann ROOS, Benyamin YAZDAN PANAH, Markus CONZELMANN, Andreas THESS, Dominik BUOB, Martin KUNZE, Veronika WAGNER
-
Publication number: 20180142275Abstract: The present invention relates to an immobilized poly(N)polymerase (PNP), methods of producing said PNP and uses thereof. Further disclosed is an enzyme reactor and kit comprising the PNP for producing polynucleotidylated ribonucleic acid poly(N)RNA)molecules which are useful in gene therapy, immunotherapy, protein replacement therapy and/or vaccination.Type: ApplicationFiled: May 2, 2016Publication date: May 24, 2018Inventors: Tilmann ROOS, Benyamin YAZDAN PANAH, Markus CONZELMANN, Veronika WAGNER